Evidence map›Paper›PMID 21459099›Full record

ArticleMutation research2011

Proofreading deficiency of Pol I increases the levels of spontaneous rpoB mutations in E. coli.

K Makiela-Dzbenska, P Jonczyk, R M Schaaper, I J Fijalkowska

Abstract read
In one paragraph

Article in Mutation research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Mutational Consequences of Ciprofloxacin in Escherichia coli.Antimicrobial agents and chemotherapy · 2016
    Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

K Makiela-DzbenskaInstitute of Biochemistry and Biophysics, Polish Academy of Sciences, Pawinskiego 5A, 02-106 Warsaw, Poland.
P Jonczyk
R M Schaaper
I J Fijalkowska
Institute of Biochemistry and Biophysics, Polish Academy of Sciences · PLNational Institute of Environmental Health Sciences · US

Funding

Mechanisms Of E. coli Replication FidelityZIAES065086 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI SCHAAPER, ROELAND · 2009 to 2025
$7.4M
MECHANISMS OF E COLI REPLICATION FIDELITYZ01ES065086 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI SCHAAPER, ROELAND · 1996 to 2008
$649k
Intramural NIH HHS Z01 ES065086Intramural NIH HHS ZIA ES065086
6 · The paper itself

Abstract

The fidelity role of DNA polymerase I in chromosomal DNA replication in E. coli was investigated using the rpoB forward target. These experiments indicated that in a strain carrying a proofreading-exonuclease-defective form of Pol I (polAexo mutant) the frequency of rpoB mutations increased by about 2-fold, consistent with a model that the fidelity of DNA polymerase I is important in controlling the overall fidelity of chromosomal DNA replication. DNA sequencing of rpoB mutants revealed that the Pol I exonuclease deficiency lead to an increase in a variety of base-substitution mutations. A polAexo mutator effect was also observed in strains defective in DNA mismatch repair and carrying the dnaE915 antimutator allele. Overall, the data are consistent with a proposed role of Pol I in the faithful completion of Okazaki fragment gaps at the replication fork.

Indexed as

DNA ReplicationMutationDNADNA, BacterialDNA-Directed RNA PolymerasesDNA Mismatch RepairDNA Polymerase IDrug Resistance, BacterialEscherichia coliEscherichia coli ProteinsRifampinDNADNA, BacterialDNA-Directed RNA PolymerasesDNA Polymerase IEscherichia coli ProteinsOkazaki fragmentsRifampinrpoB protein, E coli

Identifiers

PMID21459099
PMCPMC3163159
OpenAlexW2134786516

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.